13:55 uur 24-10-2018

Optos kondigt samenwerking aan voor het monitoren en behandelen van droge leeftijdsgerelateerde maculaire degeneratie in Europa

DUNFERMLINE, Schotland–(BUSINESS WIRE)– Optos Plc, een dochteronderneming van Nikon Corporation, Japan en het enige ultra-widefield retinale beeldvormingsbedrijf voor oogzorg is blij om een exclusieve distributie-overeenkomst in Europa en Australië aan te mogen kondigen voor MacuLogix en LumiThera producten. Door het sluiten van deze overeenkomst, bieden wij nu een uitgebreide oplossing aan voor het visualiseren, identificeren en behandelen van leeftijd-gerelateerde maculaire degeneratie (AMD), een van de grootste oorzaken van blindheid in de wereld.

Dit driedelige aanbod omvat ultrabreedveldoptomap® -kleur en autofluorescentie retinale beelden om de structuur en functie van het netvliespigment epitheel (RPE) te laten zien waar AMD zich in het oog manifesteert. De MacuLogix AdaptDx, een donkere adaptometer die gebruikt kan worden om AMD te detecteren in een subklinisch stadium ten minste drie jaar voordat structurele veranderingen zoals drusen zichtbaar worden. En het Valeda™ Light Delivery System van LumiThera, het eerste goedgekeurde systeem voor de behandeling van droge leeftijdsgebonden maculadegeneratie met behulp van fotobiomodulatie.

Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe

DUNFERMLINE, Scotland–(BUSINESS WIRE)– Optos Plc, a subsidiary of Nikon Corporation, Japan and the only ultra-widefield retinal imaging company for eye care is pleased to announce an exclusive distribution agreement in Europe and Australia for MacuLogix and LumiThera products. By entering this arrangement, we now offer a comprehensive solution to visualize, identify, and treat age-related macular degeneration (AMD), one of the leading causes of blindness in the world.

This three-part offering includes ultra-widefield optomap® colour and autofluorescence retinal images to show the structure and function of the retinal pigment epithelium (RPE) where AMD manifests within the eye. The MacuLogix AdaptDx, a dark adaptometer that can be used to detect AMD at a subclinical stage at least three years before structural changes such as drusen are visible. And the LumiThera’s Valeda™ Light Delivery System, the first approved for treatment for dry age-related macular degeneration using photobiomodulation.

“We are pleased to enter this relationship with MacuLogix and LumiThera to combat AMD. This strategic solution to monitor and treat AMD is very important for the patients who have this complicated, degenerative disease”, stated Robert Kennedy, Chief Executive Officer, Optos. “We believe these two companies have complementary products to ultra-widefield retinal imaging that would provide a differentiated offering for AMD patients. The MacuLogix device can early diagnose AMD and the Lumithera medical device offers a differentiated treatment path”.

“Optos is one of the largest and most-respected suppliers of retina-focused medical devices in the world and MacuLogix is extremely honored to enter into this international partnership with them,” said William McPhee, President and CEO of MacuLogix. “By expanding our distribution network to include these eight countries, the AdaptDx will reach an additional 260 million people. Partnering with the Optos team gets us one step closer to our company’s vision of eliminating blindness caused by AMD.”

Clark Tedford, Ph.D., LumiThera President and CEO stated, “The distribution agreement with Optos allows LumiThera to begin commercialization throughout Europe and establishes a collaboration with a partner in the retinal imaging area. Optos is the global leader in ultra-widefield retinal imaging technologies and we are honored to be working with them to open up a new age in the treatment of AMD.”

About MacuLogix, Inc.

MacuLogix® equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx®, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx® dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx®. Visit www.maculogix.com for additional information.

About LumiThera, Inc.

LumiThera is a commercial-stage medical device company focused on treating people affected by ocular disorders and diseases including dry AMD, a leading cause of blindness in adults over 65. The Company is a leader in the use of photobiomodulation for the treatment of acute and chronic ocular diseases and disorders. The Company is developing the office-based Valeda™ Light Delivery System to be used by eye care specialists as medical treatments.

The device has been granted authorization to use the CE Mark by a EU Notified Body as required for commercial use in the European Union only. Valeda™ is not approved for use by the Food & Drug Administration (FDA) in the USA. Visit www.lumithera.com for additional information about the company.

About Optos

Optos is the leading ultra-widefield retinal imaging company, acquired by Nikon in 2015. Its core technology, ultra-widefield (UWF™) high resolution digital images (optomap®) capture approximately 82% and 200◦ of the retina, something no other device is capable of doing in a single image. In 2018, the company announced a new product offering that combines ultra-widefield retinal imaging and optical coherence tomography (OCT) scans. For more information about Optos, please visit www.optos.com.

 

Contacts

Optos Plc
Leslie Amodei
VP, Global Marketing
(508) 787-1414
Lamodei@optos.com

 

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is. Check out our twitter: @NewsNovumpr